A CHAMIGRENIC COMPOUND AS A NAEGLERIA FOWLERI INFECTION TREATMENT.

Patent number:

P202230496

Islas Canarias.svg
No items found.

The invention discloses the use of a sesquiterpene compound for the treatment or prevention of primary amebic meningoencephalitis (PAM) caused by Naegleria fowleri in a human or animal subject, preferably of the compound (+)- elatol, and the pharmaceutical composition containing said compound.

Countries:
Spain
Regions:
Canary Islands
Centers:
UNIVERSIDAD DE LA LAGUNA
Other entities:
Universidad Federal de Río de Janeiro
Sectors:
Chemicals
Subsectors:
TRL Level:
TRL 3 – experimental proof of concept
BRL Level:
PDF Link:
Download here
Video Link:
Watch it here
Sustainable Development Goal:
SDG03: Good health and well-being
Applications

High selectivity index Low toxicity values Alternative to existing treatments Treatment of diseases caused by "brain-eating amoeba"

Comments

Other related patents

Chemicals

HEXOSE DERIVATIVES, PREPARATION AND USES THEREOF

Countries
Portugal
Know more
Chemicals

POST-SYNTHESIS PROCEDURE FOR MODIFYING THE SURFACE OF SUPERPARAMAGNETIC NANOPARTICLES OF IRON OXIDES

Countries
Spain
Know more
Health
Chemicals

TERPENE BASED THERAPEUTIC DEEP EUTECTIC SYSTEM, METHOD OF OBTAINING AND USES THEREOF

Countries
Portugal
Know more
Get back to patents directory